NCT07523711进行中（未招募）1 期
A Phase 1, Open-label Study to Assess the Effect of Maridebart Cafraglutide (AMG 133) on the Pharmacokinetics of Oral Contraceptives in Postmenopausal Female Participants Living With Overweight or Obesity
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen
- 入组人数
- 49
- 试验地点
- 2
- 主要终点
- Area Under the Concentration-time Curve (AUC) from Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of COC
研究概览
简要总结
The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Participants must be postmenopausal females 45 to 65 years of age. Postmenopausal status must be confirmed based on the protocol-defined criteria.
- •Body mass index must be ≥ 25.0 and ≤ 38.0 kg/m^
- •Body weight must be stable, with less than 5 kg self-reported change in the 3 months before screening.
- •Participants must not have changed their diet or started a nutritional lifestyle modification program within 3 months before screening.
- •Other inclusion criteria may apply.
排除标准
- •History or evidence of any clinically significant medical condition, abnormal physical exam, ECG, vital sign, or laboratory finding that could increase risk or interfere with study participation.
- •History of diabetes, active diabetes, or hemoglobin A1c 6.5% or higher.
- •Endocrine disorders that can cause obesity, such as Cushing's syndrome.
- •History of acute or chronic pancreatitis within 1 year before check-in, pancreatic enzyme elevations greater than 2 times the upper limit of normal, or fasting triglycerides greater than 300 mg/dL.
- •Bleeding or clotting disorders, abnormal coagulation tests, or a history of venous or arterial blood clots or conditions that increase clot risk.
- •LDL cholesterol greater than 159 mg/dL.
- •Migraine with aura, normal pressure hydrocephalus, or ischemic optic neuropathy.
- •Malignancy within the past 5 years, except nonmelanoma skin cancer.
- •Unexplained postmenopausal vaginal bleeding, untreated endometrial disease, or other gynecologic conditions that could worsen with estrogen/progestin therapy.
- •Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, or uncontrolled thyroid disease.
- •Gastroparesis, inability to swallow oral medication, clinically important gastrointestinal disease, malabsorption, uncontrolled inflammatory bowel disease, certain gastrointestinal surgeries, or recent bariatric surgery.
- •Clinically significant cardiovascular disease, clinically significant arrhythmia, long QT syndrome, QTcF greater than 470 msec, second- or third-degree atrioventricular block, or clinically important abnormal pulse rate or systolic blood pressure > 150 mmHg or < 90 mmHg, diastolic blood pressure > 95 mmHg or < 50 mmHg.
- •Allergy, hypersensitivity, intolerance, or contraindication to maridebart cafraglutide, ethinyl estradiol, or orgestimate.
- •Reduced kidney function with estimated glomerular filtration rate 60 mL/min/1.73 m^2 or lower, ALT or AST greater than 2 times the upper limit of normal, or a history of acute or chronic liver disease, hepatic adenoma, or hepatic carcinoma.
- •Hemoglobin or hematocrit below the lower limit of normal.
- •Positive HIV test, or positive hepatitis B surface antigen or hepatitis C antibody at screening.
- •Lifetime history of suicide attempt, non-suicidal self-injury within 5 years, or unstable major depressive disorder or other severe psychiatric disorder within 2 years.
- •Positive pregnancy test at screening or check-in.
- •Recent use of medications that could affect study participation, including most prescription or over-the-counter medications, systemic hormone replacement therapy, certain contraceptive hormones, CYP enzyme inducers or inhibitors, GLP-1 receptor or GIP receptor agents, and nonpermitted herbal products, vitamins, or supplements.
- •Recent participation in another investigational study, prior participation in this study, or prior exposure to maridebart cafraglutide.
- •Tobacco or nicotine use within 3 months before check-in, positive cotinine test, history of alcoholism or drug abuse, positive alcohol or illicit drug testing, recent illicit drug use, or unwillingness to avoid illicit drugs or cannabinoids during the study.
- •Recent blood, plasma, or platelet donation.
- •Other exclusion criteria may apply.
研究组 & 干预措施
COC + Maridebart Cafraglutide
Experimental
Participants will receive COC orally and maridebart cafraglutide subcutaneously (SC).
干预措施: COC (Drug)
COC + Maridebart Cafraglutide
Experimental
Participants will receive COC orally and maridebart cafraglutide subcutaneously (SC).
干预措施: Maridebart Cafraglutide (Drug)
结局指标
主要结局
Area Under the Concentration-time Curve (AUC) from Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of COC
时间窗: Day 1 up to Day 89
AUC from Time Zero Extrapolated to Infinity (AUCinf) of COC
时间窗: Day 1 up to Day 89
Maximum Observed Concentration (Cmax) of COC
时间窗: Day 1 up to Day 89
次要结局
- Plasma Concentrations of Maridebart Cafraglutide(Up to Day 142)
- Number of Participants with Treatment-emergent Adverse Events (TEAEs)(Day 1 to end of trial (approximately 142 days))
- Number of Participants with Serious Adverse Events (SAEs)(From screening (Day -28) up to end of trial (approximately 170 days))
- Number of Participants Who Develop Anti-maridebart Cafraglutide Antibodies(Up to Day 142)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightOverweight or Obesity and Elevated Liver FatNCT07441252Amgen180
已完成
1 期
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous PresentationsNCT07313761Amgen349
招募中
3 期
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)2024-516654-22-00Amgen Inc.2,787
招募中
1 期
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNCT07411560Novo Nordisk A/S100
招募中
3 期
Maridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy (MARITIME-OSA-1)2025-522703-14-00Amgen Inc.45